Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.32 (
phosphoenolpyruvate carboxykinase
)
4,204
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The levels and characteristics of growth hormone (GH)-binding protein (
GHBP
) and the distribution of GH in peripheral circulation between the free and the bound fractions were studied in three lines of transgenic mice with various degrees of overexpression of bovine (b) GH gene. Two serum fractions bound GH specifically: one with low affinity and high capacity (GHBPI) and one with high affinity and low capacity (GHBPII). The
GHBP
binding capacity in normal mice (both sexes), transgenic male mice that express the metallothionein-I-hybrid bGH genes, transgenic female mice that express
phosphoenolpyruvate carboxykinase
(
PEPCK
)-bGH hybrid genes (
PEPCK
-bGH-1), and transgenic
PEPCK
-bGH-5 animals was 1.1 +/- 0.2, 2.0 +/- 0.1, 3.0 +/- 0.1, and 3.9 +/- 0.6 pmol/ml serum, respectively. The amount of GH bound to
GHBP
in transgenic animals vs. normal siblings was increased 1.8-, 2.5-, and 3.9-fold in these three lines. Consequently, the levels of GH-
GHBP
complexes in the circulation of
PEPCK
-bGH-1 transgenic mice were increased approximately 10-fold. Specific
GHBP
radioimmunoassay confirmed a threefold increase in
GHBP
in
PEPCK
-bGH-1 transgenic animals. The levels of
GHBP
were not significantly correlated to serum GH within or between lines, perhaps due to elevation of serum GH in
PEPCK
-bGH mice above the level producing maximal response. From these and previous studies, we conclude that life-long exposure to supranormal GH levels leads to major shifts in GH binding in the circulation and in the GH target organs.
...
PMID:Growth hormone-binding protein in normal mice and in transgenic mice expressing bovine growth hormone gene. 773 75